Phathom Pharmaceuticals (PHAT) Share-based Compensation (2019 - 2026)

Phathom Pharmaceuticals (PHAT) has 8 years of Share-based Compensation data on file, last reported at $20.1 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 262.82% year-over-year to $20.1 million in Q1 2026; TTM through Mar 2026 was $20.1 million, a 16.11% decrease from a year earlier, with the FY2025 full-year figure at $28.7 million, up 19.43% from the prior year.
• Share-based Compensation for Q1 2026 stood at $20.1 million, up from $5.6 million in the prior quarter.
• Over the last five years, Share-based Compensation for PHAT reached as high as $24.6 million in Q4 2023 and fell as low as $5.5 million in Q1 2025.
• Historically, Share-based Compensation has averaged $8.4 million across 5 years, with a median of $6.1 million in 2023.
• Across the five-year window, Share-based Compensation surged 269.3% in 2023 and slumped 72.8% in 2024, its largest moves.
• Year by year, Share-based Compensation stood at $6.7 million in 2022, then jumped by 269.3% to $24.6 million in 2023, then sank by 72.8% to $6.7 million in 2024, then slipped by 16.11% to $5.6 million in 2025, then soared by 258.29% to $20.1 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $20.1 million in Q1 2026, $5.6 million in Q4 2025, and $9.3 million in Q3 2025.